BENGALURU, February 27, 2026:
Abbott, a global leader in healthcare, has announced a strategic collaboration with Novo Nordisk India to commercialize Extensior®, a GLP-1 receptor agonist (RA) therapy, for people living with type 2 diabetes in India. The partnership combines Novo Nordisk’s scientific expertise in GLP-1s with Abbott’s extensive distribution network, aiming to make high-quality, evidence-based diabetes therapy more accessible across the country. Extensior® serves as a second brand of Ozempic®, one of the world’s most prescribed GLP-1 RA molecules.
Approved as an adjunct to diet and exercise, Extensior® helps adults with type 2 diabetes manage blood sugar while providing additional health benefits. The active molecule, semaglutide, has been shown to significantly reduce HbA1c levels, support weight loss, and lower the risk of cardiovascular and kidney events in patients. Backed by over 44 clinical trials and more than 10 real-world studies, semaglutide has demonstrated safety and efficacy across diabetes, obesity, and heart, liver, and kidney conditions, with nearly a decade of global use and over 49 million patient years across all semaglutide products.
Kartik Rajendran, Managing Director of Abbott India, highlighted the significance of this launch, saying, “India faces one of the fastest-growing diabetes burdens globally. Extensior® strengthens Abbott’s focus on holistic diabetes management, from medicines to diagnostics, continuous glucose monitoring, and diabetes-specific nutrition. This partnership ensures that high-quality therapies reach people with diabetes across every stage of their journey.”
Vikrant Shrotriya, Managing Director of Novo Nordisk India, added, “Semaglutide represents a major advancement in diabetes care, improving metabolic, renal, and cardiovascular health. Our collaboration with Abbott will expand access to this innovative therapy for people living with type 2 diabetes in India.”
Diabetes is a pressing health issue in India, affecting over 100 million individuals, with numbers projected to rise to 150 million by 2050. Rapid urbanization, aging populations, increasing obesity, and lifestyle changes are driving this surge. Cardiovascular and kidney complications are major risks for patients, yet 43% of those with diabetes remain undiagnosed, limiting early intervention. National diabetes-related expenditure has already crossed USD 9.8 billion (INR 88,000+ crore), underscoring the urgent need for accessible, effective treatments.
The launch of Extensior® marks a significant step in providing Indian patients with a comprehensive solution for type 2 diabetes, supporting better health outcomes through innovative, evidence-based care.Meta Description: Abbott and Novo Nordisk India partner to launch Extensior® for type 2 diabetes, offering holistic care and improved health outcomes.
Subscribe Deshwale on YouTube
